To check the efficacy if Telmisartan in Raynauds phenomenon associated with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Phase 2
- Conditions
- Health Condition 1: M056- Rheumatoid arthritis with involvement of other organs and systemsHealth Condition 2: M321- Systemic lupus erythematosus withorgan or system involvement
- Registration Number
- CTRI/2024/07/069868
- Lead Sponsor
- Institute of Medical Sciences Banaras Hindu University Varanasi Uttar Pradesh 221005
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age greater than or equal to 18 years.
2. Patients diagnosed as Systemic Lupus Erythematosus and Rheumatoid Arthritis
with history of Raynaud’s Phenomenon.
3. Willing to give signed written consent.
Exclusion Criteria
1.Any co-existing significant/incapacitating chronic illness
2.Patient with symptomatic CAD
3.Patients on oral or sublingual nitrates
4.Patient who are pregnant or reproductive couples who have intention of pregnancy
5.Patients with known contraindication to either of IPs or SOC
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in severity and frequency of Raynauds Phenomenon after introduction of drug with standard of careTimepoint: 0,6 and 12 weeks
- Secondary Outcome Measures
Name Time Method Any untoward effect or hypersensitivityTimepoint: At 1 and 2 weeks